Business context and reporting period
Incyte Corporation’s Form 10-K covers the fiscal year ended December 31, 2016; it is an annual report, not a standalone fourth-quarter filing. Incyte is a biopharmaceutical company focused on drug development and commercialization. Its principal marketed product was U.S. JAKAFI (ruxolitinib); following its June 2016 acquisition of ARIAD’s European operations, it also marketed ICLUSIG (ponatinib) in Europe and certain other countries. Novartis markets ruxolitinib outside the United States as JAKAVI.
Financial results and position
| Metric | FY 2016 | FY 2015 |
|---|---|---|
| Total revenue | $1,105.7 million | $753.8 million |
| Product revenue | $882.4 million | $601.0 million |
| JAKAFI revenue | $852.8 million | $601.0 million |
| ICLUSIG revenue | $29.6 million, from acquisition date | None reported |
| JAKAVI royalties | $110.7 million | $74.8 million |
| Operating income | $145.0 million | $50.7 million |
| Net income | $104.2 million; diluted EPS $0.54 | $6.5 million; diluted EPS $0.03 |
| Operating cash flow | $304.8 million | $86.5 million |
| Cash, cash equivalents and marketable securities | $808.5 million | $707.8 million |
| Working capital | $720.7 million | $674.4 million |
Revenue increased about 47%. Management attributed JAKAFI’s increase to $195.5 million of volume growth and $56.3 million of price growth; ICLUSIG contributed following the acquisition. Operating margin was approximately 13.1% and net margin approximately 9.4%. These are calculated from reported operating income and net income divided by total revenue. Product cost was $58.2 million, including U.S. JAKAFI royalties to Novartis and ICLUSIG intangible amortization; the filing does not present a comparable standalone gross margin.
Research and development expense rose to $581.9 million from $479.5 million; selling, general and administrative expense rose to $303.3 million from $196.6 million. FY 2016 included $96.2 million of stock-based compensation and a $17.4 million noncash charge from remeasurement of ARIAD-related contingent consideration. Investing cash use was $232.5 million, including $142.9 million net cash for the acquisition and $120.3 million of capital expenditures. Financing cash provided was $58.6 million.
At year-end, total assets were $1.64 billion and stockholders’ equity $419.5 million. Convertible notes had $749.8 million principal outstanding ($375.0 million due 2018 and $374.8 million due 2020); their carrying value was $651.5 million. Interest expense was $38.7 million, including $31.6 million of noncash debt-discount amortization. The company reported no dividends and said available cash and marketable securities were expected to fund capital needs for at least the next 12 months.
Material changes, outlook and risks
- The ARIAD acquisition expanded Incyte’s European commercial footprint and added ICLUSIG. The purchase price consideration was preliminarily valued at $440.5 million, including $147.5 million cash and $293.0 million fair value of contingent consideration. ICLUSIG generated $29.6 million revenue from acquisition through year-end and the acquired business reported a $48.7 million net loss for that period, including acquisition accounting effects and related costs.
- Pipeline activity expanded, including pivotal development plans for ruxolitinib in essential thrombocythemia and graft-versus-host disease, and Phase III development of epacadostat with pembrolizumab in melanoma. Management expected several additional pivotal or Phase III programs to begin in 2017. These are plans, not assured outcomes.
- Baricitinib received European Commission approval in February 2017. The FDA extended its review by three months to evaluate additional analyses; Incyte expected a $65 million European approval milestone in Q1 2017 and stated it was entitled to a $100 million milestone upon U.S. approval, which it expected in 2017. Approval and timing remained uncertain.
- Subsequent to year-end, Incyte agreed to pay Merus $120 million upfront for a bispecific-antibody collaboration and invested $80 million in Merus shares. It also licensed Calithera’s arginase inhibitor program, paid $45 million upfront, and committed to development funding and potential milestones. These commitments add to pipeline investment and execution risk.
- Key risks include dependence on JAKAFI, reimbursement and pricing pressure, clinical and regulatory uncertainty, competition, reliance on third-party manufacturers, and substantial debt. Incyte disclosed a February 2016 generic-drug application challenging JAKAFI patents. The filing also notes ICLUSIG’s prior European safety review and the possibility of further regulatory action.
- Incyte reported no legal proceedings under Item 3. Its financial statements received an unqualified audit opinion. Management and the auditor excluded the acquired European subsidiary from the year-end internal-control assessment; that subsidiary represented approximately 28% of assets and 3% of revenue.
The filing provides no specific consolidated revenue or earnings guidance. Management’s stated liquidity outlook was that available cash and marketable securities would cover capital needs for at least 12 months.
Important facts for investors to verify
- JAKAFI’s continuing sales growth, realized pricing, rebate and chargeback accruals, and exposure to the disclosed generic patent challenge.
- Whether baricitinib obtains U.S. approval, the resulting milestone timing, and Incyte’s 30% co-development funding obligations in selected indications.
- ICLUSIG’s European sales, safety and reimbursement trajectory, the assumptions behind contingent consideration, and the potential ARIAD buy-back provision.
- Clinical progress and funding needs for epacadostat, ruxolitinib in GVHD, and other pivotal programs; trial outcomes and approvals are not assured.
- Debt repayment and conversion plans, future cash generation, and the scale and returns of post-year-end Merus, Calithera and other collaboration commitments.